Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.

IF 4.2 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiac Failure Review Pub Date : 2022-07-01 eCollection Date: 2022-01-01 DOI:10.15420/cfr.2022.12

Joanna M Bilak, Uazman Alam, Christopher A Miller, Gerry P McCann, Jayanth R Arnold, Prathap Kanagala

{"title":"Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.","authors":"Joanna M Bilak, Uazman Alam, Christopher A Miller, Gerry P McCann, Jayanth R Arnold, Prathap Kanagala","doi":"10.15420/cfr.2022.12","DOIUrl":null,"url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) currently accounts for approximately half of all new heart failure cases in the community. HFpEF is closely associated with chronic lifestyle-related diseases, such as obesity and type 2 diabetes, and clinical outcomes are worse in those with than without comorbidities. HFpEF is pathophysiologically distinct from heart failure with reduced ejection fraction, which may explain, in part, the disparity of treatment options available between the two heart failure phenotypes. The mechanisms underlying HFpEF are complex, with coronary microvascular dysfunction (MVD) being proposed as a potential key driver in its pathophysiology. In this review, the authors highlight the evidence implicating MVD in HFpEF pathophysiology, the diagnostic approaches for identifying MVD (both invasive and non-invasive) and the prevalence and prognostic significance of MVD.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"8 ","pages":"e24"},"PeriodicalIF":4.2000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/f7/cfr-08-e24.PMC9274364.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac Failure Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/cfr.2022.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Heart failure with preserved ejection fraction (HFpEF) currently accounts for approximately half of all new heart failure cases in the community. HFpEF is closely associated with chronic lifestyle-related diseases, such as obesity and type 2 diabetes, and clinical outcomes are worse in those with than without comorbidities. HFpEF is pathophysiologically distinct from heart failure with reduced ejection fraction, which may explain, in part, the disparity of treatment options available between the two heart failure phenotypes. The mechanisms underlying HFpEF are complex, with coronary microvascular dysfunction (MVD) being proposed as a potential key driver in its pathophysiology. In this review, the authors highlight the evidence implicating MVD in HFpEF pathophysiology, the diagnostic approaches for identifying MVD (both invasive and non-invasive) and the prevalence and prognostic significance of MVD.

Abstract Image

查看原文本刊更多论文

射血分数保留型心力衰竭的微血管功能障碍：病理生理学、评估、发病率和预后。

目前，射血分数保留型心力衰竭（HFpEF）约占社区新发心力衰竭病例的一半。HFpEF 与慢性生活方式相关疾病（如肥胖和 2 型糖尿病）密切相关，有合并症者的临床预后比无合并症者差。HFpEF 在病理生理学上不同于射血分数降低的心力衰竭，这可能在一定程度上解释了这两种心力衰竭表型之间治疗方案的差异。HFpEF 的发病机制十分复杂，冠状动脉微血管功能障碍（MVD）被认为是其病理生理学的潜在关键驱动因素。在这篇综述中，作者强调了 MVD 与 HFpEF 病理生理学有关的证据、识别 MVD 的诊断方法（有创和无创）以及 MVD 的患病率和预后意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiac Failure Review

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

9 weeks